{
    "root": "35d8f763-8f98-f5ea-fae8-1367b638e82c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ABIGALE",
    "value": "20240917",
    "ingredients": [
        {
            "name": "ESTRADIOL",
            "code": "4TI98Z838E"
        },
        {
            "name": "NORETHINDRONE ACETATE",
            "code": "9S44LIC7OJ"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        }
    ],
    "indications": "abigale abigale lo indicated :",
    "contraindications": "estrogen-alone , combination progestogen , lowest effective dose shortest duration consistent treatment goals risks individual woman . reevaluate postmenopausal women periodically clinically appropriate determine whether treatment still necessary .",
    "warningsAndPrecautions": null,
    "adverseReactions": "abigale abigale lo contraindicated women following conditions : undiagnosed abnormal genital bleeding [ ( 5.2 ) ] breast cancer history breast cancer [ ( 5.2 ) ] estrogen-dependent neoplasia [ ( 5.2 ) ] active dvt , pe , history conditions [ ( 5.1 ) ] active arterial thromboembolic disease ( example , stroke myocardial infarction ) , history conditions [ ( 5.1 ) ] known anaphylactic reaction , angioedema , hypersensitivity abigale abigale lo hepatic impairment disease protein c , protein , antithrombin deficiency , known thrombophilic disorders",
    "indications_original": "Abigale and Abigale Lo are indicated for:",
    "contraindications_original": "Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Reevaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary.",
    "adverseReactions_original": "Abigale and Abigale Lo are contraindicated in women with any of the following conditions:\n                  \n                     \n                        Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.2)] \n                        \n                     \n                     \n                        Breast cancer or history of breast cancer [see Warnings and Precautions (5.2)] \n                        \n                     \n                     \n                        Estrogen-dependent neoplasia [see Warnings and Precautions (5.2)] \n                        \n                     \n                     \n                        Active DVT, PE, or history of these conditions [see Warnings and Precautions (5.1)] \n                        \n                     \n                     \n                        Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions [see Warnings and Precautions (5.1)] \n                        \n                     \n                     \n                        Known anaphylactic reaction, angioedema, or hypersensitivity to Abigale or Abigale Lo\n                     \n                     \n                        Hepatic impairment or disease\n                     \n                     \n                        Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders"
}